RZLT - NASDAQ
Rezolute, Inc.
$4.58
+14%Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotRezolute, Inc. Management Team
Mr. Daron G. Evans M.B.A., M.S.
Chief Financial Officer
Compensation
$183,040
Dr. Brian Kenneth Roberts M.D.
Chief Medical Officer
Compensation
$712,035
Dr. Davelyn Eaves Hood M.B.A., M.D.
Director and Head of Scientific & Patient Affairs
Mr. Nevan Charles Elam J.D.
Founder, Chief Executive Officer, Principal Financial Officer & Acting Chairman of the Board
Compensation
$915,668
Ms. Erin O'Boyle
Senior Vice President & Head of Clinical Operations
Mr. Michael R. Deperro
Senior Vice President & Head of Corporate Development
Mr. Michael Covarrubias
Senior Vice President & Head of Program & Portfolio Management
Mr. Chris Milks
Vice President & Head of Finance
Dr. Raj Agrawal M.D.
Vice President & Head of Ophthalmological Clinical Development
Ms. Robyn Sweinhart
Vice President & Head of Quality
Rezolute, Inc. Insider Positioning
During the last 12 months, insiders have purchased $6.00M worth of RZLT shares, with no selling activity reported.
3 Months
10.0K
28.50K
0
0.00
+29K
+$29K
3-6 Months
73.7K
127.79K
0
0.00
+128K
+$128K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
1.5M
5.84M
0
0.00
+5.8M
+$5.84M
Top Buyers
Kim Young-Jin
Director
$4.00M
Karnawat Sunil Ratilal
Officer: Chief Commercial Officer
$1.80M
Evans Daron
Officer: Cfo
$119K
Roberts Brian Kenneth
Officer: Chief Medical Officer
$59K
Kreher Nerissa
Director
$10K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $6.00M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
RZLT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | October 07, 2025 | November 19, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | October 21, 2024 | December 05, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 15, 2024 | May 16, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 12, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 16, 2022 | June 16, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | May 26, 2021 | 2021 | |
DEF 14A DEF 14A 2019 N/A | September 23, 2019 | October 23, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | April 05, 2019 | April 24, 2019 | 2019 | |
DEF 14A DEF 14A 2017 N/A | October 20, 2017 | November 28, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.